American association of clinical endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Polycystic ovary syndrome writing committee

Endocrine Practice

Volumn 11, Issue 2, 2005, Pages 126-134

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANDROGEN; C REACTIVE PROTEIN; EZETIMIBE; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYPROGESTERONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE; TRIACYLGLYCEROL;

AGE; ANAMNESIS; ARTICLE; AWARENESS; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DRUG MECHANISM; DYSLIPIDEMIA; ECHOGRAPHY; ENDOCRINOLOGY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYPERTENSION; LABORATORY TEST; LIFESTYLE; MEDICAL INFORMATION; MEDICAL PRACTICE; MEDICAL SPECIALIST; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENDOCRINOLOGY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC DISEASES; POLYCYSTIC OVARY SYNDROME; SOCIETIES, MEDICAL; UNITED STATES;

EID: 18744381558     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-2749.
2. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:671-683.
3. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003; 24:302-312.
4. Ayala C, Steinberger E, Smith KD, Rodriguez-Rigau L, Petak SM. Serum testosterone levels and reference ranges in reproductive-age women. Endocr Pract. 1999;5:322-329.
5. Futterweit W. Pathophysiology of polycystic ovarian syndrome. In: Redmond GP, ed. Androgenic Disorders. New York: Raven Press, 1995: 77-166.
6. Futterweit W, Scher J, Nunez AE, Strauss L, Rayfield EJ. A case of bilateral dermoid cysts, insulin resistance, and polycystic ovarian disease: association of ovarian tumors with polycystic ovaries with review of the literature. Mt Sinai J Med. 1983;50:251-255.
7. Insulin Resistance Syndrome Task Force. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:236-252.
8. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of the metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52:908-915.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-2497.
10. McLaughlin T, Abbasi F, Kim HS, Lamendola C, Schaaf P, Reaven G. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. Metabolism. 2001;50:795-800.
11. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38: 1165-1174.
12. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002; 77:1095-1105.
13. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:1273-1276.
14. Nestler JE. Insulin resistance syndrome and polycystic ovary syndrome. Endocr Pract. 2003;9(Suppl 2):86-89.
15. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:942-947.
16. Talbott EO, Zborowski JV, Boudreaux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol. 2004;56:27-39.
17. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141-146.
18. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165-169.
19. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:1017-1023.
20. Solomon CG, Hu FB, Dunaif A, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA. 2001;286:2421-2426.
21. Mak KH, Haffner SM. Diabetes abolishes the gender gap in coronary heart disease. Eur Heart J. 2003;24:1385-1386.
22. Alexander CM, Landsman PB, Teutsch SM, Haffner SM (Third National Health and Nutrition Examination Survey [NHANES III], National Cholesterol Education Program [NCEP]). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214.
23. Knowler WC, Barrett-Connor E, Fowler SE, et al (Diabetes Prevention Program Research Group). Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
24. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (Troglitazone in the Prevention of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Contrl Clin Trials. 1998; 19:217-231.
25. ACE Consensus Statement Writing Committee. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002; 8(Suppl 1):5-11.
26. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentration and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61:946-951.
27. Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol. 1998;51:415-422.
28. Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril. 2000; 73:150-156.
29. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802-809.
30. Dejager S, Pichard C, Giral P, et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf). 2001;54:455-462.
31. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607-613.
32. Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995;15:821-826.
33. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001;103:1410-1415.
34. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:742-746.
35. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab. 2001;86:4666-4673.
36. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2006;52:595-600.
37. Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril. 1992;57:505-513.
38. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992;37:119-125.
39. Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod. 1996;11:23-28.
40. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improved defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108-2116.
41. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86:2453-2455.
42. Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004; 89:2160-2165.
43. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
44. Nestler JE. Polycystic ovarian syndrome: metabolic and cardiovascular complications. In: Kreisberg RA, program director. Clinical Endocrinology Update 2003 Syllabus. Chevy Chase, MD: The Endocrine Society Press, 2003: 299-303.
45. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF II, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2562-2568.
46. Talbott E, Zborowski JV, McHugh-Pemu K, et al. Metabolic cardiovascular syndrome and its relationship to coronary calcification in women with polycystic ovarian syndrome. Presented at: 3rd International Workshop on Insulin Resistance, February 17-19, 2003, New Orleans, LA.
47. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:5454-5461.
48. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000;20:2414-2421.
49. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992;71:599-604.
50. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary heart disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod. 2000;15:785-789.
51. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med. 1997;126:32-35.
52. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries - a common finding in normal women. Lancet. 1988; 1:870-872.
53. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod. 2001;16:556-560.
54. Talbott E, Zborowski J, Boudreaux M. Polycystic ovary syndrome (PCOS): the effect on cardiovascular health and disease risk. In: Daya S, Harrison RF, Kempers RD, eds. Advances in Fertility and Reproductive Medicine: Proceedings of the 18th World Congress on Fertility and Sterility, Montreal, Canada, May 23-28, 2004. International Congress Series, 1266. New York, NY: Elsevier, 2004: 233-240.
55. Orio F Jr, Palomba S, Cascella T, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:4588-4593.
56. Wild RA, Grubb B, Hartz A, Van Nort JJ, Bachman W, Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril. 1990;54:255-259.
57. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab. 2002;87:2013-2017.
58. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol. 1998;51:581-586.
59. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281: 1291-1297.
60. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab. 1997;82:4075-4079.
61. Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz DJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril. 2002;77:209-215.
62. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril. 1999;71:323-327.
63. Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril. 2004;81:624-629.
64. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82:893-902.